Worth reading
71In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
5500
¥ million (consolidated revenue target for the fiscal year ending March 2030)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
FormulatedNet Sales+95.7%
基準 2,811Target5,500million
Operating profit+395.0%
基準 202Target1,000million
Operating profit margin+11.0pt
基準 7.2Target18.2%
Each line is the climb from the baseline the document states to the target it sets. The slope is scaled against the largest climb in this document. For metrics expressed as percentages, differences are shown in percentage points (pt).The increase shown by the dotted line is calculated from the two reported figures because the company did not provide the amount of growth.
What happened to the previous planFull-year consolidated earnings forecast for the fiscal year ending March 2026 → Actual results for the fiscal year ending March 20260.0%Calculated from the two disclosed figures
Key initiatives
01Domestic Business Growth
02Promotion of advanced research and development using umbilical cords and umbilical cord blood
03Expansion of the Southeast Asian business
Plan assumptionsThe CAGR of the Southeast Asian umbilical cord blood banking market is 16.8%., Conversion at ¥157.05 per US dollar (MUFG TTM as of 8 May 2026), Estimated Singapore market size: 30,000 births × 20% storage rate = 6,000 cases, Estimated Indonesia market size: 300,000 births × 1% storage rate = 3,000 cases
Segment targetSegment Domestic Business / FY03/2027 Net Sales 3,000 / Operating profit 300 / FY03/2028 Net Sales 3,300 / Operating profit 429 / FY03/2029 Net Sales 3,600 / Operating profit 540 / FY03/2030 Net Sales 4,000 / Operating profit 625, Segment Overseas Business / FY03/2027 Net Sales 100 / Operating profit -200 / FY03/2028 Net Sales 500 / Operating profit 0 / FY03/2029 Net Sales 1,000 / Operating profit 200 / FY03/2030 Net Sales 1,500 / Operating profit 375
Non-financial targetsIndicator name Number of specimens stored in Japan / Target value 20,000 specimens / Timing Not disclosed, Indicator name Domestic storage rate / Target value 3% / Timing Not disclosed, Indicator name Singapore market share / Target value 50% / Timing Medium- to Long-Term Outlook, Indicator name Indonesia market share / Target value 50% / Timing Medium- to Long-Term Outlook
Size of the Target MarketMarket Southeast Asian cord blood banking market / 2024 Approximately ¥49.6 billion ($3.16 billion) / 2032 Approximately ¥171.2 billion ($1.09 billion) / Growth rate CAGR 16.8% / Source Credence Research（https://www.credenceresearch.com/report/south-east-asia-umbilical-cord-blood-market）
Risks identified by the company
The risk that research on umbilical cord blood and umbilical cords in the field of regenerative medicine may not progress as expected, that therapeutic effects may not be confirmed, or that other effective treatments may emerge
The risk of revisions to or tightening of laws and regulations governing the cell banking business, the enactment of new laws and regulations, and deviations or accidents in cell processing and facility operations
The risk of revocation or other action concerning the manufacturing license for specified processed cellular products at cell culture and processing facilities
The risk of infrastructure and resource disruptions caused by natural disasters and other events, including earthquakes, power outages, and interruptions in the supply of reagents and liquid nitrogen
| Item | Details |
|---|---|
| Plan name | Medium-Term Management Plan (2027–2030) |
| Plan period | 2027-2030 |
| Progress against the plan | Formulated |
| Sales Target | ¥2,811 million → ¥5,500 million（+95.7%） |
| Operating profit target | ¥202 million → ¥1,000 million（+395.0%） |
| Operating profit margin target | 7.2% → 18.2%（+152.8%） |
| Segment target | Segment Domestic Business / FY03/2027 Net Sales 3,000 / Operating profit 300 / FY03/2028 Net Sales 3,300 / Operating profit 429 / FY03/2029 Net Sales 3,600 / Operating profit 540 / FY03/2030 Net Sales 4,000 / Operating profit 625, Segment Overseas Business / FY03/2027 Net Sales 100 / Operating profit -200 / FY03/2028 Net Sales 500 / Operating profit 0 / FY03/2029 Net Sales 1,000 / Operating profit 200 / FY03/2030 Net Sales 1,500 / Operating profit 375 |
| Non-financial targets | Indicator name Number of specimens stored in Japan / Target value 20,000 specimens / Timing Not disclosed, Indicator name Domestic storage rate / Target value 3% / Timing Not disclosed, Indicator name Singapore market share / Target value 50% / Timing Medium- to Long-Term Outlook, Indicator name Indonesia market share / Target value 50% / Timing Medium- to Long-Term Outlook |
| Plan assumptions | The CAGR of the Southeast Asian umbilical cord blood banking market is 16.8%., Conversion at ¥157.05 per US dollar (MUFG TTM as of 8 May 2026), Estimated Singapore market size: 30,000 births × 20% storage rate = 6,000 cases, Estimated Indonesia market size: 300,000 births × 1% storage rate = 3,000 cases |
| Key initiatives | Domestic Business Growth, Promotion of advanced research and development using umbilical cords and umbilical cord blood, Expansion of the Southeast Asian business |
| Results under the previous plan | Full-year consolidated earnings forecast for the fiscal year ending March 2026 → Actual results for the fiscal year ending March 2026 |
| Size of the Target Market | Market Southeast Asian cord blood banking market / 2024 Approximately ¥49.6 billion ($3.16 billion) / 2032 Approximately ¥171.2 billion ($1.09 billion) / Growth rate CAGR 16.8% / Source Credence Research（https://www.credenceresearch.com/report/south-east-asia-umbilical-cord-blood-market） |
| Risks identified | The risk that research on umbilical cord blood and umbilical cords in the field of regenerative medicine may not progress as expected, that therapeutic effects may not be confirmed, or that other effective treatments may emerge, The risk of revisions to or tightening of laws and regulations governing the cell banking business, the enactment of new laws and regulations, and deviations or accidents in cell processing and facility operations, The risk of revocation or other action concerning the manufacturing license for specified processed cellular products at cell culture and processing facilities, The risk of infrastructure and resource disruptions caused by natural disasters and other events, including earthquakes, power outages, and interruptions in the supply of reagents and liquid nitrogen |
| Publication date | 23 June 2026 |
Items this document does not state (11)
Net income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planInvestment amount by sectorReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.With the Singapore business entering full-scale operations, we have clarified “domestic business growth” and “expansion into Southeast Asian markets” as the two pillars of our growth strategy. In Japan, we will expand storage-fee revenue by increasing new storage and the cumulative number of stored specimens, while seeking to establish the Southeast Asian business as a future earnings pillar and enhance corporate value over the medium to long term.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.